A Multiple-center, Multiple-dose, Randomized, Double-blind, Double-dummy, Placebo-controlled, Positive-controlled, Parallel Group Study to Investigate the Effect of RO4917838 on the QTc Interval in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 15 Sep 2015
At a glance
- Drugs Bitopertin (Primary) ; Moxifloxacin
- Indications Bacterial infections; Schizophrenia
- Focus Adverse reactions
- Sponsors Roche
- 11 Sep 2012 Results published in Clinical Therapeutics.
- 12 Aug 2012 Primary endpoint 'noninferiority between bitopertin and placebo in QT-interval changes at steady state' has been met.
- 08 Jun 2012 New source identified and integrated: ClinicalTrials.gov record NCT01613040.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History